TransCode Therapeutics Appoints Life Sciences Veteran Jack E. Stover to Board of Directors

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has appointed Jack E. Stover to its Board of Directors, where he will serve on the Audit Committee and the Nominating Committee. This appointment coincides with Dr. Magda Marquet stepping down from the Audit Committee. Mr. Stover brings more than 30 years of executive leadership experience across public and private life sciences companies, with a background spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation. His extensive expertise is expected to contribute operational, financial, and strategic guidance as TransCode advances its RNA and immuno-oncology pipeline for the treatment of high-risk and advanced cancers.

The appointment of Mr. Stover comes at a critical juncture for TransCode, a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. TransCode's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. This strategic board addition underscores the company's focus on advancing innovative cancer treatments through RNA technology.

TransCode maintains a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery, potentially unlocking therapeutic access to various novel genetic targets relevant to treating multiple cancers. The company's latest news and updates are available in its newsroom at https://ibn.fm/RNAZ. This board appointment signals TransCode's commitment to strengthening its leadership as it progresses its clinical development programs, with Mr. Stover's experience expected to provide valuable insights during this important growth phase.

The broader investment community can access detailed information about TransCode through specialized financial communications platforms. InvestorWire, a specialized communications platform with advanced wire-grade press release syndication, provides comprehensive coverage for public companies like TransCode. This platform offers access to a vast network of wire solutions via InvestorWire to efficiently reach target markets, demographics, and diverse industries. For more information about these financial communication services, visit https://www.InvestorWire.com.